251 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
Celldex (CLDX): What's Ahead for the Stock in Q2 Earnings? http://www.zacks.com/stock/news/226771/celldex-cldx-whats-ahead-for-the-stock-in-q2-earnings?cid=CS-ZC-FT-226771 Aug 04, 2016 - With no approved product in its portfolio, investors will remain focused on pipeline related updates from Celldex (CLDX).
Allergan (AGN) Q2 Earnings: Will the Stock Disappoint? http://www.zacks.com/stock/news/226764/allergan-agn-q2-earnings-will-the-stock-disappoint?cid=CS-ZC-FT-226764 Aug 04, 2016 - Allergan's (AGN) Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is a negative 1.49% - will the stock disappoint?
Repros (RPRX) Q2 Earnings: What's in Store for the Stock? http://www.zacks.com/stock/news/226752/repros-rprx-q2-earnings-whats-in-store-for-the-stock?cid=CS-ZC-FT-226752 Aug 04, 2016 - With Repros being a development-stage company, investors will remain focused on the company's pipeline and cash burn.
Kite (KITE) Q2 Earnings: What's in Store for the Stock? http://www.zacks.com/stock/news/226712/kite-kite-q2-earnings-whats-in-store-for-the-stock?cid=CS-ZC-FT-226712 Aug 04, 2016 - With Kite (KITE) being a development stage company, investor focus will remain on the company's pipeline updates and cash burn.
ARIAD's (ARIA) Stock Up on Q2 Earnings & Revenue Beat http://www.zacks.com/stock/news/225805/ariads-aria-stock-up-on-q2-earnings-revenue-beat?cid=CS-ZC-FT-225805 Jul 29, 2016 - ARIAD (ARIA) swung to earnings in the second quarter while Iclusig sales continued to grow.
ARIAD (ARIA) to Report Q2 Earnings: Will the Stock Surprise? http://www.zacks.com/stock/news/224914/ariad-aria-to-report-q2-earnings-will-the-stock-surprise?cid=CS-ZC-FT-224914 Jul 26, 2016 - Focus will remain on the performance of ARIAD's (ARIA) leukemia drug, Iclusig.
Eli Lilly (LLY) May Beat Q2 Earnings: Will the Stock Gain? http://www.zacks.com/stock/news/224276/eli-lilly-lly-may-beat-q2-earnings-will-the-stock-gain?cid=CS-ZC-FT-224276 Jul 21, 2016 - The combination of Lilly's Zacks Rank #3 and +1.18% ESP makes us very confident in looking for a positive earnings beat on Jul 26.
Incyte (INCY) CEO Herve Hoppenot Presents at Morgan Stanley 2015 Global Healthcare Conference (Transcript) http://seekingalpha.com/article/3518516-incyte-incy-ceo-herve-hoppenot-presents-at-morgan-stanley-2015-global-healthcare-conference-transcript?source=feed_sector_healthcare Sep 17, 2015 - Incyte Corporation (NASDAQ:INCY) Morgan Stanley 2015 Global Healthcare Conference Call September 17, 2015 12:20 PM ET Executives Herve Hoppenot – President and Chief Executive Officer Analysts Andrew
Aduro-Incyte in Clinical Trial Agreement for Ovarian Cancer http://www.zacks.com/stock/news/189800/aduro-incyte-in-clinical-trial-agreement-for-ovarian-cancer?cid=CS-ZC-FT-189800 Sep 11, 2015 - Aduro (ADRO) signed a clinical study agreement with Incyte (INCY) to evaluate CRS-207, in combination with Incyte's epacadostat, in patients with ovarian cancer.
Increased Earnings Estimates Seen for Incyte Corporation (INCY): Can It Move Higher? http://www.zacks.com/stock/news/188957/incyte-corporation-incy-a-biopharmaceutical-company-could-be-an-interesting-play-for-investors?cid=CS-ZC-FT-188957 Sep 04, 2015 - The positive earnings estimate revisions suggest that analysts are becoming more optimistic on Incyte Corporation’s earnings for the coming quarter and year

Pages: 1...20212223242526

<<<Page 25